Monica M. Mita, MD


Dr. Mita on Treatment Selection in ER+, HER2- Breast Cancer

Monica M. Mita, MD, discusses treatment selection for patients with estrogen receptor–positive, HER2-negative breast cancer.

Suchita Pakkala, MD


Dr. Pakkala on Integrating Local Therapy into HER2+ Breast Cancer Treatment

Suchita Pakkala, MD, discusses ongoing efforts to integrate local therapy into HER2-positive breast cancer treatment.

Sapna Patel, BA, MD


Dr. Patel on the Sequencing of Immunotherapy and Targeted Therapy in BRAF-Mutant Melanoma

Sapna Patel, BA, MD, discusses the sequencing of immunotherapy and targeted therapy in BRAF-mutant melanoma.

Jathin Bandari, MD


ASCO GU 2022: Piecing Together Prostate Cancer Data With Drs. Tanya Dorff and Jathin Bandari

OncLive speaks with Drs. Tanya Dorff and Jathin Bandari on some exciting prostate cancer studies.

Tisch Cancer Institute


Mount Sinai Researchers Discover How Early-Stage Breast Cancer Can Become a Silent Killer in Some Patients

Mount Sinai researchers have discovered a previously unknown mechanism in which not-yet-malignant cells from early breast cancer tumors travel to other organs and, eventually, “turn on” and become metastatic breast cancer.

Phulong L. Mai, MD


Dr. Mai on Barriers of Genetic Testing in CRC

Phuong L. Mai, MD, discusses barriers of genetic testing in colorectal cancer.

Meriem Mokhtech, MD


Creating the In-Person Experience on a Virtual Platform

The coronavirus disease 2019 crisis has changed all aspects of medical education but perhaps altered clinical education most dramatically.

John Crown, BCh, BAO, BSc, MD, MBA


Dr. Crown on the Role of Eribulin Mesylate in TNBC

John Crown, BCh, BAO, BSc, MD, MBA, discusses the role of eribulin mesylate in triple-negative breast cancer.

Alexandre A. Jácome, MD, PhD


Charting the Course for Patients With High-Risk Colon Cancer: 3 Months Versus 6 Months

In 5 years, it is estimated that approximately 20% of patients with stage II disease and 35% with stage III disease will experience disease recurrence. These estimates highlight the need to pursue progress in adjuvant systemic therapy in order to decrease recurrence rates and improve survival.

Milana Dolezal, MD, MSci


Considering Novel Therapy for HER2+ Metastatic Breast Cancer

A summary of sequencing therapy in the HER2+ metastatic breast cancer treatment paradigm followed by excitement for novel therapies under investigation.

Anita D’Souza, MD


Dr. D’Souza on the Utilization of Monoclonal Antibodies and Immunomodulating Agents in AL Amyloidosis

Anita D’Souza, MD, discusses the utilization of monoclonal antibodies and immunomodulating agents in patients with light chain amyloidosis.

Jason Westin MD, FACP


Dr. Westin on Second-line CAR T-cell Therapy in Relapsed/Refractory DLBCL

Jason Westin, MD, FACP, discusses reasons to refer patients with diffuse large B-cell lymphoma to second-line CAR T-cell therapy, CAR T-cell eligibility criteria, and high-risk disease features that may further support the use of CAR T-cell therapy in the second line, rather than chemotherapy.

Patrick Pilie, MD


Dr. Piliè on the Benefit of Second-Generation AR Inhibitors in Nonmetastatic CRPC

Patrick Piliè, MD, discusses the benefit of second-generation androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.

Alice Chen, MD


Dr. Naqash and Dr. Chen on the Efficacy of Atezolizumab in Advanced Alveolar Soft Part Sarcoma

Abdul Rafeh Naqash, MD, and Alice Chen, MD, discuss their phase 2 trial evaluating the efficacy of atezolizumab in patients with advanced alveolar soft part sarcoma.

Marjorie G. Zauderer, MD


Dr. Zauderer on the Importance of Optimizing Care in Mesothelioma

Marjorie G. Zauderer, MD, discusses the importance of optimizing care for patients with mesothelioma.

Allison Winter, MD


Dr. Winter on Emerging Agents in CLL

Allison Winter, MD, discusses emerging agents in chronic lymphocytic leukemia.

Dana Farengo Clark, MS, LCGC, Penn Medicine


Operational Processes and Challenges

Mark Robson, MD; John Henson, MD; Ashley Ross, MD, PhD; and Dana Farengo Clark, MS, LCGC, discuss operational processes and techniques for counseling patients about germline testing.

Yael Simons, MD


Dr. Simons on Racial Disparities Reported in Luminal Breast Cancer

Yael Simons, MD, discusses the racial disparities seen in African Americans patients with luminal breast cancer.

Bhuvaneswari Ramaswamy, MD


Dr. Ramaswamy on Determining Treatment Courses in Metastatic HER2+ Breast Cancer

Bhuvaneswari Ramaswamy, MD, discusses determining treatment courses for individual patients with HER2-positive breast cancer.

Susan Tsai, MD, MHS


Dr. Tsai on Ongoing Research Efforts in Pancreatic Cancer

Susan Tsai, MD, MHS, discusses ongoing research efforts being made in the realm of pancreatic cancer. 

Carolina Bernabe, MD


Survey Aims to Identify COVID-19–Related Health Care Challenges in Latin America

Outbreaks of coronavirus disease 2019 are on the rise in Latin America, with more than 4 million confirmed cases. In response to this health crisis, elective medical procedures, including cancer screening and care, as well as treatment for conditions beyond the virus, have been held.

Loretta J. Nastoupil, MD


Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)

Dr Loretta J. Nastoupil details key efficacy data from the TRANSFORM trial investigating lisocabtagene as a second-line therapy for R/R LBCL, and Dr Marc S Hoffman comments on how to decide on an appropriate treatment in the second-line setting for high-risk R/R LBCL.

David H. Harpole Jr, MD


Therapies Targeting Specific Molecular Alterations in NSCLC

A panel of distinguished experts discuss how detection of actionable mutations affect their treatment choices in non-small cell lung cancer.

Vamsidhar Velcheti, MD, NYU Langone Health


Second-Line Treatment of SCLC

Vamsidhar Velcheti, MD, leads the discussion on the current standard of care and approaching the treatment of second-line SCLC.

Stephanie Berg, DO


Dr. Berg on the Role of the PEACE-1 and ARASENS Trials in Expanding mHSPC Treatment

Stephanie Berg, DO, discusses two key clinical trials that have advanced the standard of care in metastatic hormone-sensitive prostate cancer.

Solange Peters, MD, PhD, Lausanne University Hospital


EGFR+ NSCLC: Advice for Community Oncologists

A panel of experts in thoracic oncology concludes the discussion by emphasizing the importance of conducting reflex molecular testing, considering systemic therapy in all patients, and utilizing shared decision-making models.

Atrium Health Wake Forest Baptist


Scientists Create Nanoparticle That Helps Fight Solid Tumors

Researchers from Wake Forest University School of Medicine have discovered a possible new approach in treating solid tumors through the creation of a novel nanoparticle.